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Scientific Abstracts Background: Dose tapering of biological therapies (BT) in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) is frequent in Spain. However, there is variability in BT optimization (BTO). So, Spanish Society of Rheumatology published in 2015 recommendations on how to optimize BT (1). Nevertheless, there is no solid evidence on which patient profiles BTO is appropriated. Objectives: To develop appropriateness criteria for BTO in patients with RA, axial SpA (axSpA) or peripheral SpA (pSpA) Methods: The RAND/UCLA appropriateness method was used. Five rheumatologists experienced in RA and/or SpA clinical research selected and defined the variables considered relevant when deciding reduction of BT in order to define patient profiles. Ten BT experienced rheumatologists anonymously rated 1 (completely inappropriate) to 9 (completely appropriate) each profile after reading evidence synthesis. Then, in a meeting, classification variables and profiles with disagreement were revised and all profiles were scored again. Profiles with a median score >6 were considered appropriate, those with a median score <3.5 were considered inappropriate and the remaining uncertain. In addition, a study of the prevalence of these profiles was performed in 9 Spanish hospitals. Results: Combining the options of variables 2,304 different profiles were obtained for RA, 768 for axSpA, and 3,072 for pSpA. 327 (14.2%) profiles in RA, 80 (10.4%) in axSpA, and 154 (5%) in pSpA were considered appropriate for BT dose reduction. By contrast, 749 (53.3%) profiles in RA, 270 (54.4%) in axSpA, and 1243 (54.5%) in pSpA were considered inappropriate. The remaining profiles were considered uncertain. In the preliminary study to determine profiles prevalence, we collected information from 242 RA, 171 axSpA and 172 pSpA patients that underwent BTO. We found that BTO was performed appropriately in 23% RA, 67% axSpA and 61% pSpA patients. BTO was indicated in uncertain profiles in 67% RA, 23% axSpA and 37% pSpA patients. Only in RA we detected BT dose reduction in patient profiles considered inappropriate (2%).
Conclusions: Appropriateness criteria for BT dose reduction in three inflammatory conditions were developed and the preliminary prevalence study suggests that BTO was wiselly applied. However, further research in this field is needed to determine the real prevalence of clinical profiles of patients undergoing BTO in daily clinical practice and validate these criteria in real life. Background: The introduction of biosimilars has been linked with concerns regarding how to best monitor their similarity vs. the originator product using real world data. Results: During the study period, a total of 1833 patients started an infliximab treatment and 1793 started etanercept. These patients were either bDMARDnaïve (patients without a history of any biological treatment), non-medical switchers (patients who switched from the originator product), or patients who had a history of a previous (but not the same) bDMARD (Table 1) . These three groups were not evenly distributed across originators or biosimilars, and had different baseline demographic and disease characteristics. The uptake in terms of treatment starts was faster for Benepali (it covered more than 90% of this part of the etanercept market after only 3 months) as compared to Remsima and Inflectra (together they accounted for 88% of this section of the infliximab market after 10 months). The uptake of biosimilars in terms of proportion of all patient on treatment was, at the end of September 2016, 27% 
